Intrinsic value of Cytosorbents - CTSO

Previous Close

$4.30

  Intrinsic Value

premium content

  Rating & Target

premium content

  Value-price divergence*

premium content

Previous close

$4.30

 
Intrinsic value premium content
 
Up/down potential premium content
 
Rating premium content
 
Value-price divergence* premium content

Premium access subscription - $499/yr

please register and log in before paying

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of CTSO stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.1

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  100.00
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  10
  8
  12
  18
  27
  38
  52
  70
  92
  118
  149
  185
  226
  273
  324
  381
  444
  511
  584
  661
  743
  830
  921
  1,017
  1,118
  1,223
  1,332
  1,446
  1,565
  1,688
  1,816
Variable operating expenses, $m
 
  22
  35
  52
  75
  106
  146
  196
  257
  330
  417
  518
  633
  764
  908
  1,068
  1,243
  1,431
  1,634
  1,851
  2,081
  2,324
  2,580
  2,849
  3,130
  3,424
  3,730
  4,049
  4,381
  4,727
  5,085
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  21
  22
  35
  52
  75
  106
  146
  196
  257
  330
  417
  518
  633
  764
  908
  1,068
  1,243
  1,431
  1,634
  1,851
  2,081
  2,324
  2,580
  2,849
  3,130
  3,424
  3,730
  4,049
  4,381
  4,727
  5,085
Operating income, $m
  -11
  -14
  -22
  -33
  -48
  -68
  -94
  -126
  -165
  -212
  -268
  -333
  -407
  -491
  -584
  -687
  -799
  -920
  -1,051
  -1,190
  -1,338
  -1,494
  -1,659
  -1,831
  -2,012
  -2,201
  -2,398
  -2,603
  -2,817
  -3,038
  -3,269
EBITDA, $m
  -11
  -14
  -22
  -33
  -47
  -67
  -92
  -124
  -162
  -209
  -264
  -328
  -400
  -483
  -574
  -675
  -785
  -905
  -1,033
  -1,170
  -1,315
  -1,469
  -1,631
  -1,801
  -1,979
  -2,164
  -2,358
  -2,560
  -2,770
  -2,988
  -3,215
Interest expense (income), $m
  0
  0
  0
  0
  0
  0
  1
  1
  1
  2
  2
  3
  3
  4
  5
  6
  7
  8
  10
  11
  12
  14
  16
  17
  19
  21
  23
  25
  27
  29
  32
Earnings before tax, $m
  -12
  -14
  -22
  -33
  -49
  -69
  -94
  -127
  -166
  -214
  -270
  -336
  -411
  -495
  -589
  -693
  -806
  -928
  -1,060
  -1,201
  -1,350
  -1,508
  -1,674
  -1,849
  -2,031
  -2,222
  -2,421
  -2,628
  -2,844
  -3,068
  -3,301
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -12
  -14
  -22
  -33
  -49
  -69
  -94
  -127
  -166
  -214
  -270
  -336
  -411
  -495
  -589
  -693
  -806
  -928
  -1,060
  -1,201
  -1,350
  -1,508
  -1,674
  -1,849
  -2,031
  -2,222
  -2,421
  -2,628
  -2,844
  -3,068
  -3,301

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  5
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  10
  5
  7
  11
  16
  23
  31
  42
  55
  71
  89
  111
  136
  164
  195
  229
  266
  307
  350
  397
  446
  498
  553
  610
  671
  734
  799
  868
  939
  1,013
  1,089
Adjusted assets (=assets-cash), $m
  5
  5
  7
  11
  16
  23
  31
  42
  55
  71
  89
  111
  136
  164
  195
  229
  266
  307
  350
  397
  446
  498
  553
  610
  671
  734
  799
  868
  939
  1,013
  1,089
Revenue / Adjusted assets
  2.000
  1.600
  1.714
  1.636
  1.688
  1.652
  1.677
  1.667
  1.673
  1.662
  1.674
  1.667
  1.662
  1.665
  1.662
  1.664
  1.669
  1.664
  1.669
  1.665
  1.666
  1.667
  1.665
  1.667
  1.666
  1.666
  1.667
  1.666
  1.667
  1.666
  1.668
Average production assets, $m
  1
  2
  4
  6
  8
  11
  16
  21
  28
  35
  45
  56
  68
  82
  97
  114
  133
  153
  175
  198
  223
  249
  276
  305
  335
  367
  400
  434
  469
  506
  545
Working capital, $m
  2
  -2
  -2
  -4
  -5
  -8
  -10
  -14
  -18
  -24
  -30
  -37
  -45
  -55
  -65
  -76
  -89
  -102
  -117
  -132
  -149
  -166
  -184
  -203
  -224
  -245
  -266
  -289
  -313
  -338
  -363
Total debt, $m
  5
  1
  4
  7
  11
  17
  25
  35
  47
  61
  77
  97
  119
  144
  172
  203
  237
  273
  312
  354
  398
  445
  494
  546
  601
  657
  716
  778
  842
  908
  978
Total liabilities, $m
  10
  4
  7
  10
  14
  20
  28
  38
  50
  64
  80
  100
  122
  147
  175
  206
  240
  276
  315
  357
  401
  448
  497
  549
  604
  660
  719
  781
  845
  911
  981
Total equity, $m
  0
  0
  1
  1
  2
  2
  3
  4
  6
  7
  9
  11
  14
  16
  19
  23
  27
  31
  35
  40
  45
  50
  55
  61
  67
  73
  80
  87
  94
  101
  109
Total liabilities and equity, $m
  10
  4
  8
  11
  16
  22
  31
  42
  56
  71
  89
  111
  136
  163
  194
  229
  267
  307
  350
  397
  446
  498
  552
  610
  671
  733
  799
  868
  939
  1,012
  1,090
Debt-to-equity ratio
  0.000
  2.750
  4.950
  6.290
  7.140
  7.680
  8.040
  8.280
  8.450
  8.580
  8.660
  8.730
  8.780
  8.820
  8.850
  8.870
  8.890
  8.900
  8.910
  8.920
  8.930
  8.940
  8.950
  8.950
  8.960
  8.960
  8.960
  8.970
  8.970
  8.970
  8.970
Adjusted equity ratio
  -1.000
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -12
  -14
  -22
  -33
  -49
  -69
  -94
  -127
  -166
  -214
  -270
  -336
  -411
  -495
  -589
  -693
  -806
  -928
  -1,060
  -1,201
  -1,350
  -1,508
  -1,674
  -1,849
  -2,031
  -2,222
  -2,421
  -2,628
  -2,844
  -3,068
  -3,301
Depreciation, amort., depletion, $m
  0
  0
  0
  1
  1
  1
  2
  2
  3
  4
  4
  6
  7
  8
  10
  11
  13
  15
  18
  20
  22
  25
  28
  31
  34
  37
  40
  43
  47
  51
  54
Funds from operations, $m
  -5
  -14
  -22
  -33
  -48
  -67
  -93
  -124
  -163
  -210
  -266
  -330
  -404
  -487
  -579
  -681
  -793
  -913
  -1,043
  -1,181
  -1,328
  -1,483
  -1,647
  -1,818
  -1,998
  -2,185
  -2,381
  -2,585
  -2,797
  -3,017
  -3,246
Change in working capital, $m
  2
  -1
  -1
  -1
  -2
  -2
  -3
  -4
  -4
  -5
  -6
  -7
  -8
  -9
  -10
  -11
  -12
  -13
  -14
  -15
  -16
  -17
  -18
  -19
  -20
  -21
  -22
  -23
  -24
  -25
  -26
Cash from operations, $m
  -7
  -14
  -21
  -32
  -46
  -65
  -90
  -121
  -159
  -205
  -260
  -323
  -396
  -478
  -569
  -670
  -780
  -900
  -1,028
  -1,165
  -1,311
  -1,466
  -1,628
  -1,799
  -1,978
  -2,164
  -2,359
  -2,562
  -2,773
  -2,993
  -3,221
Maintenance CAPEX, $m
  0
  0
  0
  0
  -1
  -1
  -1
  -2
  -2
  -3
  -4
  -4
  -6
  -7
  -8
  -10
  -11
  -13
  -15
  -18
  -20
  -22
  -25
  -28
  -31
  -34
  -37
  -40
  -43
  -47
  -51
New CAPEX, $m
  -1
  -1
  -1
  -2
  -3
  -3
  -4
  -5
  -7
  -8
  -9
  -11
  -12
  -14
  -16
  -17
  -19
  -20
  -22
  -23
  -25
  -26
  -27
  -29
  -30
  -31
  -33
  -34
  -36
  -37
  -38
Cash from investing activities, $m
  2
  -1
  -1
  -2
  -4
  -4
  -5
  -7
  -9
  -11
  -13
  -15
  -18
  -21
  -24
  -27
  -30
  -33
  -37
  -41
  -45
  -48
  -52
  -57
  -61
  -65
  -70
  -74
  -79
  -84
  -89
Free cash flow, $m
  -5
  -15
  -23
  -34
  -49
  -69
  -95
  -128
  -168
  -216
  -273
  -338
  -413
  -498
  -593
  -697
  -810
  -933
  -1,065
  -1,206
  -1,356
  -1,514
  -1,681
  -1,855
  -2,038
  -2,229
  -2,429
  -2,636
  -2,852
  -3,077
  -3,310
Issuance/(repayment) of debt, $m
  5
  1
  2
  3
  5
  6
  8
  10
  12
  14
  17
  19
  22
  25
  28
  31
  34
  36
  39
  42
  44
  47
  49
  52
  54
  57
  59
  62
  64
  67
  69
Issuance/(repurchase) of shares, $m
  0
  6
  21
  31
  45
  64
  88
  119
  157
  203
  258
  321
  394
  476
  568
  669
  780
  901
  1,030
  1,169
  1,316
  1,472
  1,637
  1,809
  1,990
  2,179
  2,376
  2,582
  2,795
  3,017
  3,248
Cash from financing (excl. dividends), $m  
  5
  7
  23
  34
  50
  70
  96
  129
  169
  217
  275
  340
  416
  501
  596
  700
  814
  937
  1,069
  1,211
  1,360
  1,519
  1,686
  1,861
  2,044
  2,236
  2,435
  2,644
  2,859
  3,084
  3,317
Total cash flow (excl. dividends), $m
  0
  -14
  -20
  -31
  -45
  -63
  -88
  -118
  -156
  -202
  -256
  -319
  -391
  -473
  -565
  -666
  -777
  -897
  -1,026
  -1,164
  -1,311
  -1,467
  -1,631
  -1,804
  -1,984
  -2,173
  -2,370
  -2,575
  -2,788
  -3,010
  -3,241
Retained Cash Flow (-), $m
  8
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -4
  -4
  -4
  -5
  -5
  -5
  -5
  -6
  -6
  -6
  -7
  -7
  -7
  -7
  -8
Prev. year cash balance distribution, $m
 
  8
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Current shareholders' claim on cash, %
  100
  50.0
  9.5
  1.8
  0.4
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

CytoSorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent polymer technology. Its principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; for the adjunctive therapy in other critical care applications; the prevention of post-operative complications of cardiopulmonary bypass surgery and damage to organs donated by brain-dead donors prior to organ harvest; the treatment of cancer cachexia; the prevention of transfusion reactions caused by contaminants in transfused blood products; and the prevention of contrast induced nephropathy, the treatment of drug overdose, and the treatment of chronic kidney failure. The company is also developing HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is developing BetaSorb device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, an extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to CytoSorbents Corporation in May 2010. CytoSorbents Corporation was founded in 1997 and is based in Monmouth Junction, New Jersey.

FINANCIAL RATIOS  of  Cytosorbents (CTSO)

Valuation Ratios
P/E Ratio -9.1
Price to Sales 11
Price to Book 0
Price to Tangible Book
Price to Cash Flow -15.7
Price to Free Cash Flow -13.7
Growth Rates
Sales Growth Rate 100%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 0%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio 5
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -114.3%
Ret/ On Assets - 3 Yr. Avg. -116.2%
Return On Total Capital -184.6%
Ret/ On T. Cap. - 3 Yr. Avg. -191.7%
Return On Equity -300%
Return On Equity - 3 Yr. Avg. -264.4%
Asset Turnover 1
Profitability Ratios
Gross Margin 60%
Gross Margin - 3 Yr. Avg. 56.7%
EBITDA Margin -120%
EBITDA Margin - 3 Yr. Avg. -176.7%
Operating Margin -110%
Oper. Margin - 3 Yr. Avg. -155%
Pre-Tax Margin -120%
Pre-Tax Margin - 3 Yr. Avg. -176.7%
Net Profit Margin -120%
Net Profit Margin - 3 Yr. Avg. -168.3%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 3.3%
Payout Ratio 0%

CTSO stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the CTSO stock intrinsic value calculation we used $5 million for the last fiscal year's total revenue generated by Cytosorbents. The default revenue input number comes from 2016 income statement of Cytosorbents. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our CTSO stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for CTSO is calculated based on our internal credit rating of Cytosorbents, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Cytosorbents.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of CTSO stock the variable cost ratio is equal to 280%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for CTSO stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for Cytosorbents.

Corporate tax rate of 27% is the nominal tax rate for Cytosorbents. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the CTSO stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for CTSO are equal to 30%.

Life of production assets of 10 years is the average useful life of capital assets used in Cytosorbents operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for CTSO is equal to -20%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $8 million for Cytosorbents - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 25.696 million for Cytosorbents is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Cytosorbents at the current share price and the inputted number of shares is $0.1 billion.


Premium access subscription - $499/yr

please register and log in before paying
RELATED COMPANIES Price Int.Val. Rating
CERS Cerus 2.56 prem.  prem.
HAE Haemonetics 39.31 prem.  prem.
KOOL Cesca Therapeu 3.12 prem.  prem.
BAX Baxter Interna 61.38 prem.  prem.
NXTM NxStage Medica 23.33 prem.  prem.
RMTI Rockwell Medic 8.52 prem.  prem.

COMPANY NEWS

▶ ETFs with exposure to CytoSorbents Corp. : May 22, 2017   [May-22-17 01:32PM  Capital Cube]
▶ CTSO: Revenue Acceleration Expected 2H. REFRESH Efficacy Compelling   [May-15-17 04:00PM  Zacks Small Cap Research]
▶ ETFs with exposure to CytoSorbents Corp. : May 9, 2017   [May-09-17 04:30PM  Capital Cube]
▶ CytoSorbents reports 1Q loss   [May-08-17 05:23PM  Associated Press]
▶ CytoSorbents Announces Positive REFRESH I Trial Results   [May-05-17 09:00AM  PR Newswire]
▶ CTSO: Equity Raise, Cancer Applications, REFRESH I Data Upcoming   [Apr-17-17 09:00AM  Zacks Small Cap Research]
▶ ETFs with exposure to CytoSorbents Corp. : April 5, 2017   [Apr-05-17 04:35PM  Capital Cube]
▶ CytoSorbents Announces Pricing of Follow-On Offering   [Mar-31-17 08:00AM  PR Newswire]
▶ CytoSorbents Announces Proposed Offering of Common Stock   [Mar-30-17 04:01PM  PR Newswire]
▶ CTSO: Several Catalysts Will Extend Record Revenue Streak Into 2017   [Mar-08-17 10:00AM  Zacks Small Cap Research]
▶ CytoSorbents Launches VetResQ for U.S. Veterinary Market   [Jan-20-17 09:00AM  PR Newswire]
▶ CytoSorbents to Present at the 2016 BIO Investor Forum   [Oct-14-16 07:00AM  PR Newswire]
Stock chart of CTSO Financial statements of CTSO Annual reports of CTSO
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.